Save the PDF to draw one Owl Card (per stock, once a day)
OWL LABS EQUITY RESEARCH
207940 · SIGNATURE REPORT OWL-260729-207940 · JULY 29, 2026
SIGNATURE QUANT PROFILE · 제약/바이오
Samsung Biologics Co.,Ltd. 207940 · KOSPI
제약/바이오 · KRW listed
OWL VERDICT
BALANCED CASE
Grade B · Score 67 / 100
LAST PRICE
₩1,481,000
▼ -4.4%
OWL FAIR VALUE
₩1,604,198
+8.3% vs price
STREET TARGET
₩2,096,122
+41.5% · 23 analysts
MARKET CAP
₩68.6T
P/E · P/B
38.4 · 9.2
ROE 23.9%
52-WEEK RANGE
1,228,000–1,987,000
now at 33th pctile
Investment Summary
01
Quality vs. price, measured. Quality axes (ROE 23.9%, op. margin 45.4%) score 40/40; value axes (P/E 38.4x, P/B 9.20x, EV/EBITDA, dividend) score 22/80. The composite 67/100 (grade B) is that arithmetic.
02
No tracked 13F position. None of the 9 tracked managers reports 207940 this quarter (13F covers US-listed instruments only) — see p.3 for each book's style lens.
03
0 of 5 value strategies pass. No mechanical screen admits 207940; the other 5 reject on their coded rules (details p.2).
04
What would change this report. Model fair value is ₩1,604,198 (+8.3% vs price); The verdict changes only when the data changes — screening reruns every weekday.
THE OWL VIEW
The data reads sound but not one-sided: composite 67/100 — 0/5 value screens pass. We grade 207940 B; the framework says the case is solid and price is the swing variable.
This report aggregates Owl Labs quant modules — 7-axis screener, 5 value strategies, 9 guru 13F filings, fair-value model, technical signals and news. All figures are measured from data sources as of the date above; sentences are rule-based templates (no generative claims). The score is a fitness test of reported fundamentals against today’s price — a screener, not a forecast; forward growth is not part of the score. Not investment advice.
207940 · SIGNATURE REPORT OWL-260729-207940 · JULY 29, 2026
Valuation — Five Value Disciplines
SECTION 02 OF 5
Each strategy is a mechanical screen coded from the discipline's published rules — a stock either passes or it does not. 207940 passes 0 of 5. Verdicts are computed, not opined; the measured inputs are shown for audit.
STRATEGY
MECHANICAL CRITERIA
VERDICT
MEASURED INPUTS
Graham Defensive
Low P/E × low P/B composite screen
FAIL
P/E×P/B 353
Greenblatt Magic Formula
Earnings yield + return on capital, top 30%
FAIL
E/P 2.6% · ROE 23.9%
Prasad Deep Value
Low P/B, low leverage, positive earnings
FAIL
P/B 9.20x
Simple DCF
OWL LABS EQUITY RESEARCH
207940 · SIGNATURE REPORT OWL-260729-207940 · JULY 29, 2026
Smart-Money Positioning — 9 Tracked Managers
SECTION 03 OF 5
Holdings from SEC 13F filings (disclosed ~45 days after quarter end). Weight = % of the manager's disclosed US long book. 13F covers US-listed instruments only — a Korean-listed share is "not reportable", not "passed over". These are filed positions — not the managers' opinions on this stock.
MANAGER
FUND
STYLE
WEIGHT
ACTION
STYLE LENS (RULE-BASED)
Warren Buffett
Berkshire Hathaway Inc.
Value
—
NO POSITION
Out of 13F scope — US-listed instruments only
Ray Dalio
Bridgewater Associates, LP
Macro
—
NO POSITION
Out of 13F scope — US-listed instruments only
OWL LABS EQUITY RESEARCH
207940 · SIGNATURE REPORT OWL-260729-207940 · JULY 29, 2026
Tape, Catalysts & Risk Register
SECTION 04 OF 5
Technical Readout as of Tue Jul 28
RSI (14d)64.7 — neutral
MACD vs signal+19059.78 above
MA20 / MA60₩1,408,700 / ₩1,390,767
Cross stateNone
Distance to 52-wk high-25.5%
52-wk range position33th percentile
Day change-4.4%
OWL LABS EQUITY RESEARCH
207940 · SIGNATURE REPORT OWL-260729-207940 · JULY 29, 2026
Financial Record & Final Judgment
SECTION 05 OF 5
FISCAL YEAR
FY2023
FY2024
FY2025
Revenue
₩3.69T
₩3.50T
₩4.56T
Operating income
₩1.11T
₩1.32T
₩2.07T
Net income
₩0.86T
₩1.08T
₩1.78T
Op. margin
30.1%
37.8%
45.4%
Net margin
23.2%
31.0%
39.2%
ROE
8.7%
9.9%
23.9%
20/20
Op. margin
20/20
EV/EBIT
2/20
Dividend
12/20
Attention
17/20
Composite (incl. adj.)67 / 100 · B
KR universe rank#185 of 1036 · top 18%
Value screens passed0 / 5
52-wk range position33%
Next earningsTBA
Axis weights are proprietary; axis names and raw scores are disclosed. Attention measures news & search interest — a crowding proxy, not a quality signal.
One-line read: 제약/바이오 name scoring 67/100 (grade B), passing 0/5 value strategies.
Conservative discounted cash flow vs price
FAIL
Model ₩1,604,198 vs ₩1,481,000
Damodaran Relative
Multiples vs sector median, growth-adjusted
FAIL
P/E 38.4x · rev +30.3%
Fair-Value Bridge method blend, measured
Growth/quality-adjusted PER (w17%)₩796,401
Justified PBR (ROE-based) (w17%)₩444,300
Analyst target (23) (w67%)₩2,096,122
Owl fair value / share₩1,604,198
Upside at ₩1,481,000+8.3%
MODEL INPUTS (DISCLOSED)
P/E · P/B38.4x · 9.20x
ROE (latest FY)23.9%
ROE (3-yr avg, normalized)14.2%
Revenue CAGR (2-yr)+11.1%
Band: FAIR · justified-multiple model with quality/growth adjustments — an estimate, not a promise.
Sensitivity value per share
EARNINGS ↓ / MULTIPLE →
-10%
base
+10%
-10%
₩645,085
₩716,761
₩788,437
base (measured)
₩716,761
₩796,401
₩876,041
+10%
₩788,437
₩876,041
₩963,645
Simple sensitivity (reference): ±10% arithmetic on the measured P/E-method value — earnings basis × fair multiple. Not a forecast; no projected figures are used.
Read this like a memo: the model says ₩1,604,198 and the Street consensus says ₩2,096,122 (23 analysts). The gap is the assumption set — both are computed from disclosed inputs above; underwrite the difference yourself.
Information only — not investment advice · Sources: exchange data · SEC EDGAR · DART · Owl Labs models
No tracked manager reports a US-listed long position in 207940 this quarter. 13F covers only US-listed instruments (e.g., ADRs) — "not held" may simply mean not reportable.
13F filings disclose US-listed long positions ~45 days after quarter end. "Style lens" lines relate this stock to each investor's public style using measured metrics only — they are not the managers' actual views. For Korean stocks, 13F covers only US-listed instruments (e.g., ADRs) — "not held" may simply mean not reportable.
Information only — not investment advice · Sources: exchange data · SEC EDGAR · DART · Owl Labs models
Measured state: RSI 64.7 (neutral), MACD above its signal, no MA cross is active. Read the tape as one input, not a verdict.
Catalyst Calendar
No confirmed earnings date in calendar
Every weekday — quant screening refreshscore update
Quarterly — 13F filing window (~45d after quarter end)13F refresh
Forward Signals (unscored) consensus data · never scored
Street target consensus₩2,096,122 (23)
Implied upside vs price+41.5%
Next-quarter EPS estimate—
Next-quarter revenue estimate—
Shown for context, never scored: the composite grades only reported fundamentals. Forward numbers are third-party consensus — treat them as the market’s assumption set, not ours.
Risk Register
MID
유상증자(지분 희석)(disclosure flag · DART)
QUANT
Crowding. Attention axis 17/20 — elevated news & search interest (a crowding proxy, not a quality signal).
MEDIUM
Drawdown state. Price sits -25.5% below the 52-week high (33th percentile of the range) — measured tape, not a judgment of cause.
LOW
No dividend cushion. Yield 0% — total return depends entirely on price; drawdowns are not buffered by income.
WHAT THE BEARS MUST PROVE / WHAT THE BULLS MUST PROVE
Bears: that the measured quality base cracks — ROE 23.9% and op. margin 45.4% are what the score leans on. Bulls: less on price — the model's ₩1,604,198 sits +8.3% above; they must show the measured fundamentals hold through the next filings.
Information only — not investment advice · Sources: exchange data · SEC EDGAR · DART · Owl Labs models
Source: company filings (annual). Only reported fiscal years are shown — no forward estimates. ROE 23.9% · Net margin 39.2%.
News Digest RSS · external media
07/22 — Samsung Biologics stock trades steady as revenue growth and capacity expansion support valuation (Ad-hoc-news.de)
07/22 — Samsung Biologics Sets Settlement Date for KRW2.7 Trillion PolyPeptide Acquisition (marketscreener.com)
07/20 — Samsung Biologics to acquire PolyPeptide in $1.8 billion deal (Business Standard)
07/20 — PolyPeptide rallies over 5% as Samsung Biologics strikes $1.8 billion deal (Investing.com Nigeria)
External media — accuracy rests with each outlet.
Methodology & how to use
Every number in this report is measured — pulled from the screener database, SEC EDGAR 13F filings, DART disclosures, company financials, or deterministic models (justified-multiple fair value). Sentences are rule-based templates bound to those numbers; nothing is generated, so nothing is hallucinated. Axis weights and the sector adjustment are proprietary; axis names, raw scores, and every input above are disclosed for audit.
Known limits, stated plainly. ① Backward-looking — the score grades reported fundamentals and today's price; future inflections (a cycle turn, next year's earnings) are not scored and appear only as unscored context (street target, catalysts). A low score can mean "great business, full price". ② The composite is this framework's ranking, not an absolute quality of the company. ③ 13F covers US-listed holdings only. Use the report as a screener; pair it with your own forward and qualitative work before acting.
B
BALANCED CASE
Final judgment. 207940 scores 67/100 (grade B) — rank #185 of 1036 in the KR universe. Axis split: quality 40/40 · value 22/80 · attention 17/20. Model fair value ₩1,604,198 (+8.3% vs price). The verdict changes only when the data changes.
Grade rubric: A 85+ (top conviction basket) · B 65+ (sound, price matters) · C 45+ (no rush) · D below (weak case). The verdict changes only when the data changes — next screening runs every weekday.
Owl Labs is an online information provider. This document is compiled from public data sources (exchange quotes, SEC EDGAR 13F, DART filings, company financials, news RSS) and Owl Labs quantitative models. It is not investment advice, not a solicitation to trade any security, and past data does not guarantee future results. Figures may differ from real-time values. Final investment decisions and responsibility rest solely with the investor. Unauthorized redistribution prohibited.
